Last reviewed · How we verify
Portia (EE and LN) or equivalent oral tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Portia (EE and LN) or equivalent oral tablet (portia-ee-and-ln-or-equivalent-oral-tablet) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Portia (EE and LN) or equivalent oral tablet TARGET | portia-ee-and-ln-or-equivalent-oral-tablet | Pfizer Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Portia (EE and LN) or equivalent oral tablet CI watch — RSS
- Portia (EE and LN) or equivalent oral tablet CI watch — Atom
- Portia (EE and LN) or equivalent oral tablet CI watch — JSON
- Portia (EE and LN) or equivalent oral tablet alone — RSS
Cite this brief
Drug Landscape (2026). Portia (EE and LN) or equivalent oral tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/portia-ee-and-ln-or-equivalent-oral-tablet. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab